In addition to strong earnings, Eli Lilly’s prospects were brightened by encouraging trial results from its obesity-drug competitor Novo Nordisk.
You are here: Home / Promise around Eli Lilly’s expected obesity drug, great earnings adds some $60 billion in market cap